Target intelligence / Profile preview

Glutamine and Asparagine (Glutamine: Gln (Q), Asparagine: Asn (N))

Target
Glutamine: Gln (Q), Asparagine: Asn (N)
Molecular classification
Amino acid, Proteinogenic amino acid, Polar, uncharged amino acid
01

Overview

Glutamine (Gln, Q) and Asparagine (Asn, N) are polar, uncharged, non-essential amino acids serving as fundamental building blocks of proteins. Glutamine is the most abundant amino acid in circulating blood, acting in nitrogen transport and as an energy/precursor substrate for rapidly dividing cells. Asparagine is important in protein synthesis, particularly N-linked glycosylation, and brain development. Both amino acids are produced endogenously in healthy humans. While not drug targets themselves, the metabolic dependencies on these amino acids are exploited by drugs such as asparaginase in leukemia, which limits the availability of asparagine to cancer cells unable to synthesize it. In summary: "Glutamine and asparagine" is not a canonical molecular target but rather refers to two separate amino acids. While central to biology and metabolism, they are not considered traditional therapeutic targets, though enzymes in their metabolic pathways are pharmacologically targeted.

Other names
Glutamine: 2-Amino-4-carbamoylbutanoic acidGlnQAsparagine: 2-Amino-3-carbamoylpropanoic acidAsnN
02

Mechanism of action

Asparaginase (enzyme drug) depletes circulating asparagine to inhibit growth of asparagine-dependent cancer cells (e.g., in acute lymphoblastic leukemia). Some experimental cancer drugs target glutamine metabolism pathways.

03

Biological functions

Protein synthesisNitrogen transport (primarily for glutamine)Nucleotide biosynthesisCellular metabolism (e.g., energy in rapidly dividing cells)Precursor or donor for other biosynthetic reactions
04

Disease associations

Cancer (amino acid metabolism/auxotrophy for glutamine in some cancers)Neurological disorders (as both amino acids are precursors in neurotransmitter pathways)Infection (role in immune metabolism)Other
05

Safety considerations

Depleting glutamine or asparagine can impair normal cell growth, immunity, and neurologic function.Enzyme therapies (asparaginase) can cause allergic reactions, pancreatitis, and coagulopathy due to off-target depletion effects.Supplementation can affect metabolic balance, particularly in liver or kidney dysfunction.
06

Interacting drugs

Asparaginase
07

Biomarkers

Not standardly used as biomarkers for therapy selectionplasma glutamine/asparagine levelsmetabolic enzyme expression

Beyond the preview

Go deeper on Glutamine and Asparagine (Glutamine: Gln (Q), Asparagine: Asn (N)).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Glutamine and Asparagine (Glutamine: Gln (Q), Asparagine: Asn (N)).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call